Bausch Health: Now Is the Time to Buy This Value Stock

Joseph Papa joined Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) a few years back and began the journey to position the company on a path for future success and growth.

| More on:
Pills spilling out of a prescription pot

Image source: Getty Images.

Joseph Papa joined Bausch Health (TSX:BHC)(NYSE:BHC) a few years back and began the journey to position the company on a path for future success and growth. While the journey is in an early stage, and there are still some legacy issues to resolve, Bausch Health appears to be on a path to stabilize the business, deliver on financial commitments and execute existing and new product opportunities.

Every day, Bausch Health focuses on opportunities to generate value for shareholders, recover relationships with the company’s partners, make positive contributions to the healthcare community, and build a special place for the company’s 20,000 employees. The company has advised that this multi-year journey will require three distinct phases, which includes turning around the business and transforming the company.

Focused on improving lives

Over the last year, Bausch Health’s attention was directed at laying the foundation for a company focused on improving peoples’ lives with healthcare products. This appears to be a philosophy that guides the company’s daily decisions and actions. A few years back, the company made some important strides. It recruited a strong new leadership team with significant industry experience and a determination to turn around the business.

Further, Bausch Health re-affirmed a commitment to uphold the highest standards of integrity and ethical corporate behaviour, and established a patient access and pricing committee to oversee pricing actions. Bausch Health realized that it could only earn back the trust of the company’s shareholders and stakeholders with transparency and therefore introduced reporting segments that offer enhanced visibility into the company’s performance.

Obtained approvals for key products

Also, Bausch Health recognized that the company’s employees are critical to being successful and has improved sales force retention rates. Bausch Health identified core areas of the company’s business where it believes the return on investment will yield long-term growth. Finally, as it refocuses research and development (R&D) investments, the company celebrated several approvals for key products including Oral Relistor, Bausch + Lomb Ultra for presbyopia and, brodalumab for moderate-to-severe psoriasis.

In addition, Bausch Health has taken the necessary steps to stabilize the company and is now focused on navigating the company’s turnaround and transformation. The company had made a commitment to paying down $5 billion in debt from divestiture proceeds and cash flows from operations within an 18-month timeframe. Since making that commitment, the company has paid down approximately $2.5 billion in debt.

Flexibility to operate the business

Furthermore, Bausch Health divested or agreed to divest a number of assets, which will reduce the complexity of the company’s portfolio and which will generate total asset sales proceeds of approximately $2.7 billion. Bausch Health made all scheduled payments due and announced key divestitures of several products in the company’s consumer skincare business and the sale of the company’s Dendreon business.

Bausch Health plans to use net proceeds from both asset sales to reduce company’s debt. Bausch Health sees opportunities to generate value for shareholders and has now also refinanced debt obligations to provide an improved near-term maturity profile. This provides more flexibility under Bausch Health’s requirements to operate the business.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool owns shares of and recommends Bausch Health Companies. Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »